Biocon planning new biomanufacturing plant in India

By Dan Stanton contact

- Last updated on GMT

Vizag, Visakhapatnam in the Andhra Pradesh region of India - location of new Biocon plant
Vizag, Visakhapatnam in the Andhra Pradesh region of India - location of new Biocon plant
Indian drugmaker and biosimilars pioneer Biocon has told the Chief Minister of Andhra Pradesh it intends to set up a new biomanufacturing plant.

According to a release from the Andhra Pradesh Government reported by a number of Indian media outlets​, Biocon’s Managing Director Kiran Shaw met Chief Minister N Chandrababu Naidu at his residence Sunday to inform him of plans for a new manufacturing facility in Vizag in the next six months.

Biopharma-Reporter.com contacted Biocon for confirmation, and a company spokesperson said: “Biocon has been planning to set up a Bio-manufacturing facility at Pharma-city SEZ [Special Economic Zone] in Vizag.” ​No specific details are being provided at this stage.

The company has already launched two proprietary monoclonal antibody drugs – Alzumab (Itolizumab) for psoriasis and Biomab (Nimotuzumab) for glioma – but the firm is also investing in insulin products through construction of a $200m facility in Malaysia set to open next year, and biosimilars.

Earlier this year, Biocon and Mylan became the first companies to launch a biosimilar in India following approval of their version of Roche’s Herceptin in December 2013​. Known as Canmab, the drug is “a testament to our significant investments in state-of-the-art research tools,”​ Biocon said in its annual report and despite being criticised by patient groups​ over its cost, is the world’s lowest priced trastuzumab.

Alzumab and Canmab are manufactured at the firm’s 200,000sq ft facility in Bangalore, one of the largest biomanufacturing plants in India, and also the site of a training academy the firm has set up​ in order to address the shortage of biotech workers in the country.

Furthermore, Biocon operates a third-party contract manufacturing subsidiary, Syngene, which – along with Kemwell – is one of two firms offering India-based biomanufacturing services to Western firms​.

Related news

Show more

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Related suppliers

Follow us

Products

View more

Webinars